Drug interactions between Carbatrol and simvastatin
| Results for the following 2 drugs: |
|---|
| Carbatrol (carbamazepine) |
| simvastatin |
Interactions between your selected drugs
carbamazepine ↔ simvastatin
Applies to:Carbatrol (carbamazepine) and simvastatin
GENERALLY AVOID: Coadministration with carbamazepine may significantly decrease the plasma concentrations of simvastatin and its pharmacologically active acid metabolite. The proposed mechanism is carbamazepine induction of the intestinal and hepatic CYP450 3A4 metabolism of simvastatin and simvastatin acid. In 12 healthy volunteers, pretreatment with carbamazepine for 14 days (200 mg once daily for 2 days, then 300 mg twice daily) decreased the mean total area under the serum concentration-time curve (AUC) of simvastatin and simvastatin acid by 75% and 82%, respectively, compared to administration of simvastatin (80 mg single oral dose) alone. In the presence of carbamazepine, the mean peak concentrations (Cmax) of both simvastatin and simvastatin acid were reduced by 68%, and the half-life of simvastatin acid was shortened from 5.9 to 3.7 hours. The interaction was apparent in every subject of the study.
MANAGEMENT: Given the magnitude of the interaction, the pharmacologic effect of simvastatin may be significantly reduced during concomitant administration with carbamazepine. Therefore, concurrent use should preferably be avoided. If the combination is prescribed, the dosage of simvastatin may need to be increased. Alternatively, use of another HMG-CoA reductase inhibitor (i.e., statin) that is not significantly metabolized by CYP450 3A4 may be considered. As carbamazepine is known to induce other CYP450 isoenzymes besides 3A4, the statins least likely to interact may be pravastatin, which is metabolized by non-CYP routes, and rosuvastatin, which is only about 10% metabolized.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
